Virtu Financial’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-13,073
Closed -$4.14M – 2345
2023
Q4
$4.14M Buy
+13,073
New +$2.54M 0.33% 38
2023
Q3
– Sell
-2,320
Closed -$503K – 2105
2023
Q2
$503K Sell
2,320
-3,550
-60% -$761K 0.04% 399
2023
Q1
$1.07M Buy
5,870
+4,765
+431% +$911K 0.11% 177
2022
Q4
$217K Sell
1,105
-3,143
-74% -$674K 0.03% 664
2022
Q3
$955K Buy
+4,248
New +$860K 0.09% 208
2021
Q3
– Sell
-4,081
Closed -$465K – 2112
2021
Q2
$465K Buy
+4,081
New +$477K 0.05% 508
2020
Q3
– Sell
-4,775
Closed -$532K – 1643
2020
Q2
$532K Buy
+4,775
New +$415K 0.06% 356
2019
Q4
$353K Buy
+4,686
New +$205K 0.03% 590

Other funds holding KRTX

Virtu Financial's KRTX Position: Q1 2024 in Review

Virtu Financial sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 13,073 shares — an estimated $4.14M sold.

Virtu Financial first reported a position in KRTX in Q4 2019 and held it in 8 quarters. The position peaked at $4.14M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Virtu Financial reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Virtu Financial sold 13,073 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.14M.
  • Virtu Financial first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
  • Virtu Financial's Karuna Therapeutics, Inc. Common Stock position peaked at $4.14M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.